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Abstract
Photodynamic therapy (PDT) is an effective clinical treatment for a number of different cancers. PDT can induce hypoxia and inflammation, pro-
angiogenic side effects, which may counteract its angio-occlusive mechanism. The combination of PDT with anti-angiogenic drugs offers a pos-
sibility for improved anti-tumour outcome. We used two tumour models to test the effects of the clinically approved angiostatic tyrosine kinase
inhibitors sunitinib, sorafenib and axitinib in combination with PDT, and compared these results with the effects of bevacizumab, the anti-VEGF
antibody, for the improvement of PDT. Best results were obtained from the combination of PDT and low-dose axitinib or sorafenib. Molecular
analysis by PCR revealed that PDT in combination with axitinib suppressed VEGFR-2 expression in tumour vasculature. Treatment with bev-
acizumab, although effective as monotherapy, did not improve PDT outcome. In order to test for tumour vessel normalization effects, axitinib
was also applied prior to PDT. The absence of improved PDT outcome in these experiments, as well as the lack of increased oxygenation in
axitinib-treated tumours, suggests that vascular normalization did not occur. The current data imply that there is a future for certain anti-
angiogenic agents to further improve the efficacy of photodynamic anti-cancer therapy.
Keywords: angiogenesis inhibitors axitinib, bevacizumab combination therapy endothelial cells photodynamic
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Introduction
Photodynamic therapy (PDT) is a minimally invasive therapy in which
visible or near infrared light irradiation is combined with light sensitive
molecules (photosensitizers) to produce reactive oxygen species
(ROS). These ROS can damage blood vessels in such a way that vascu-
lar occlusion occurs [1]. Several photosensitizers have been approved
by the FDA to treat a number of oncological applications by PDT (see
Table S1). Photodynamic therapy is also used in ophthalmology [2]
and for many years PDT was the mainstay for treating exudative age-
related macular degeneration, the main cause of blindness in the aged
western population [3]. Angio-occlusive PDT can cause tissue
responses, such as hypoxia and inflammation [1], both of which play a
role in inducing angiogenesis [4]. This angiogenic tissue response fol-
lowing PDT can in principle counteract the angio-occlusive effect of
PDT, thus leading to a reduced tumoricidal outcome. Therefore, PDT
results may be improved by co-treatment with an angiogenesis inhibi-
tor. We previously showed in a tumour-free model that vessel regrowth
after angio-occlusive PDT can effectively be inhibited by anti-angio-
genic agents [5]. In the present study, we tested the effect of combin-
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ing PDT with an anti-angiogenic drug by monitoring tumour vascula-
ture and tumour growth. This was done in two different tumour models
on the chorioallantoic membrane (CAM) of the chicken embryo.
Therapeutic anti-angiogenesis strategies have been established in
the clinical management of cancer, both as monotherapies [6] and in
combination with other anti-tumour modalities [7]. Among these are
bevacizumab (Avastin, an antibody-based drug that neutralizes
VEGF), and the broad-spectrum (tyrosine) kinase inhibitors (TKIs)
that inhibit the signalling of growth factor receptors. Examples of the
latter are sunitinib (Sutent), clinically approved for the treatment of
metastatic renal cell carcinoma [6], imatinib-resistant gastrointestinal
stromal- and pancreatic neuroendocrine tumours [8, 9]. We also
tested sorafenib (Nexavar), approved for metastatic renal cell cancer
and unresectable hepatocellular carcinoma [10]. While sunitinib inhib-
its VEGF receptors 1, 2 and 3 (VEGFR-1, -2 and -3), platelet-derived
growth factor receptor beta (PDGFR-b) and mast/stem cell growth
factor receptor (c-KIT) with medium affinity, and FGFR-1 with low
affinity [11], sorafenib inhibits the RAF/MEK/ERK pathways, as well
as VEGFR-1, -2 and -3, c-KIT and PDGFR-b with relatively low affinity
[10]. A second-generation TKI with improved affinity to VEGFR-2 and
a better toxicity profile, is axitinib (Inlyta) [12]. Axitinib has fewer
targets and has a higher affinity for the VEGF receptors [13]. It should
be noted that the combination of PDT with the antibody-based agents
bevacizumab and ranibizumab has been tested clinically for the treat-
ment of wet age-related macular degeneration [14]. For cancer, only
pre-clinical studies are available. Very limited research has been
focused so far on the combination of PDT with TKIs [15].
It has previously been shown that angiogenesis inhibition can nor-
malize cancer vessels [16]. As the efficacy of PDT depends on tissue
oxygenation, we tested sequencing of the combination therapy. We
found that PDT treatment can be significantly improved by angiostatic
compounds. The tested TKIs were more effective enhancers of PDT
effects than bevacizumab. In addition, anti-angiogenic drugs were
found to be best applied after PDT. These results, as well as tissue
oxygenation measurements, suggested that the observed improve-
ments were not dependent on vascular normalization.
Materials and methods
Cell culture, preparation and implantation on the
CAM model
A2780 human ovarian carcinoma cells (ECACC, Salisbury, UK) were
maintained in RPMI-1640 cell culture medium supplemented with Gluta-
MAXTM (Gibco, Carlsbad, CA, USA), 10% bovine calf serum (Sigma-
Aldrich, St. Louis, MO, USA) and 1% antibiotics (Sigma-Aldrich).
Human colorectal carcinoma (HCT-116; ECACC) cells were maintained
in DMEM medium (Gibco) supplemented as above. Fertilized chicken
eggs were incubated in a hatching incubator (relative humidity 65%,
37°C), as previously described [17]. On EDD 7, 106 HCT-116 cells were
mixed with ice-cold Matrigel (BD Biosciences, Franklin Lakes, NJ, USA)
and transplanted on the surface of the CAM as a 30 ll drop. 106 A2780
cells were prepared as a spheroid in a 25 ll hanging drop and 3 hrs
later were transplanted on the surface of the CAM [18].
Image acquisition and quantification
Visualization of the CAM vasculature and irradiation with light during
PDT was performed under an epi-fluorescence microscope (Eclipse E
600 FN; Nikon AG, Tokyo, Japan) with objectives (Plan Apo 49/0.2,
working distance: 20 mm or Plan Fluor 109/0.3, working distance:
16 mm; Nikon AG), as previously described [19]. Shortly, PDT was per-
formed (kex = 420  20 nm, kem ≥ 470 nm; Nikon) using Visudyne
(Novartis Pharma Inc., Hettlingen, Switzerland). Visualization of blood
vessels was achieved through fluorescence angiography after intrave-
nous (i.v.) injection of fluorescein isothiocyanate dextran (FITC-dextran,
20 kD, 20 ll, 25 mg/ml, Sigma-Aldrich). A volume of 20 ll of India ink
from Pelikan (Witzikon, Switzerland) was administered to enhance vas-
cular contrast. Fluorescence images were taken using an F-view II 12-
bit monochrome Peltier-cooled digital CCD camera run by ‘analySIS
DOCU’ software (Soft Imaging System GmbH, Munster, Germany).
Image processing and quantification of the fluorescence angiographies
was achieved by using a macro written in ImageJ (version 1.40 a;
National Institutes of Health, Bethesda, MD, USA), as previously
described [20]. The four concentric circles with ‘1’ being the central
area, and ‘4’ being the most peripheral area, create four zones of revas-
cularization, each of which is analysed separately by the software.
Combination therapy on the CAM
Bevacizumab was purchased from Genentech (San Francisco, CA, USA),
sunitinib from Pfizer Inc. (New York, NY, USA), axitinib and sorafenib
from LC Laboratories (Woburn, MA, USA). Drugs were administered
intravenously (20 ll) on EDD 10 and 11 at two concentrations: axitinib
(6.5 or 13 lg/kg), sorafenib (21 or 85 lg/kg), sunitinib (35.5 or 71 lg/
kg) and bevacizumab (99 or 497 lg/kg). Concentrations were calculated
for an estimated embryo weight of 3 g [21]. Angiograms of the CAM
were taken on EDD 12. Visudyne-PDT (subsequently referred to as
PDT) was performed at a low-fluence rate (5 J/cm2, with irradiance of
35 mW/cm2 at 420  20 nm). The irradiation area was limited to a cir-
cular spot of 0.02 cm2 using an optical diaphragm. Directly after PDT,
20 ll of the angiogenesis inhibitors was administered intravenously in
the CAM at the following effective doses: axitinib (13 lg/kg), sorafenib
(85 lg/kg), sunitinib (71 lg/kg) and bevacizumab (497 lg/kg). Treat-
ment was repeated 24 hrs after PDT.
Tumour treatment
Vascularized tumours appeared ~3 days after inoculation beneath the
surface of the CAM and the average tumour volume was
1.66  0.09 mm3. Visudyne-PDT, as described above, was performed
at this moment, while adjusting the diaphragm to the tumour size. An-
giostatic therapy was performed by administering 20 ll of axitinib
(13 lg/kg), sorafenib (85 lg/kg), sunitinib (71 lg/kg) and bevacizumab
(497 lg/kg) intravenously at EDD 10 and 11.
Combination therapy
Tumours receiving combination treatment were injected twice intrave-
nously with 20 ll of each angiogenesis inhibitor (at doses as above)
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
481
J. Cell. Mol. Med. Vol 18, No 3, 2014
according to two different schedules: (i) right after PDT and 24 hrs after
PDT or (ii) 24 hrs before PDT and right after PDT (Fig. 6A). Photody-
namic therapy with 5 J/cm2 and 35 mW/cm2 at 420  20 nm was
applied. Tumours were measured daily, volume = (the largest diame-
ter)2 9 (perpendicular diameter) 9 0.5.
Immunohistochemistry
Tumours were resected at treatment day 8, fixed overnight in zinc fix-
ative solution [22] and stained as previously described [23]. In short,
4 lm sections were treated with 0.3% H2O2 in methanol for 30 min., a
citrate buffer (20 min. at 95°C) antigen retrieval step was applied,
blocking with 10% goat serum and 1% BSA was performed. Primary
antibody (DIA-310; Dianova, Hamburg, Germany) incubations were per-
formed overnight.
RNA isolation, cDNA synthesis and quantitative
real-time RT-PCR
Total RNA isolation, cDNA synthesis and quantitative real-time RT-PCR
(qRT-PCR) were performed as previously described [5]. Each target
gene was quantified relative to the expression of the reference genes
(b-Actin and Cyclophilin-A). Chicken (gg) and human (hs) primers were
synthesized by Eurogentec (Liege, Belgium) [24].
pO2 measurements
Intra-tumoral oxygenation was measured 24 hrs after the first treatment
intervention (corresponding to treatment day 2). Measurements of the
partial pressure of oxygen (pO2) within the treated tumours were
obtained using an OxyLab pO2 meter (Oxford Optronix Ltd., Oxford, UK)
coupled to a calibrated fibre optic probe (NP/O/E) placed in a 23G sur-
gical steel needle. Each measurement was taken over 60 sec. after the
intra-tumoral probe insertion.
Statistical analysis
Values are given as mean values  SEM. Data are represented as aver-
ages of independent experiments. Statistical analysis was done using
the ANOVA test and t-test. *P indicating P-values lower than 0.05 and
**P indicating P-values lower than 0.01 were considered statistically
significant. Synergy was calculated using the CompuSyn application
[25].
Results
Clinically used angiostatic TKIs prolong the
vaso-occlusive effect of PDT
Visudyne-PDT (PDT) was performed on the CAM at embryo
development day (EDD) 10 (Fig. 1A), leading to blood flow stasis in
the smaller blood vessels and in the capillary bed. Vessels with a
diameter >70 lm stayed perfused (Fig. 1B). New capillaries were first
seen in the most peripheral zone of the treated area (Fig. 1B) and a
completely regrown vasculature was observed after 48 hrs (Fig. 1C).
Quantification of the data was performed by digital image analysis in
four concentric areas (Fig. 1C, most right image).
To prolong the effect of PDT, treatment with anti-angiogenic
compounds, axitinib, sorafenib, sunitinib or bevacizumab, was per-
formed. Angiostatic compounds were first tested alone by adminis-
tering i.v. injection on EDD 10 and 11, followed by imaging and
quantification performed on EDD 12. Representative fluorescence
images of the CAM treated with 0.9% NaCl (control) or axitinib
(13 lg/kg) are presented in Fig. 1D and 1E, respectively. Low con-
centrations of all four drugs were identified where a statistically sig-
nificant inhibitory effect was observed (**P < 0.01, Fig. 1F). These
doses were tested in combination with PDT. All drugs were adminis-
tered twice, immediately after PDT and 24 hrs later. Interestingly, all
three tested TKIs markedly suppressed the regrowth of blood ves-
sels, as determined by a significant reduction in the number of
branching points. This activity was not observed for bevacizumab.
Axitinib and sunitinib were the most effective drugs (Fig. 1G and H).
An ~90% reduction in the number of branching points per mm2 was
observed in treatment area 1, while bevacizumab was completely
ineffective.
Angiostatic TKIs, but not bevacizumab, improve
the anti-tumour effect of PDT
A2780 ovarian carcinoma cells were inoculated at EDD 7 and moni-
tored for 11 days. Established and vascularized tumours were
detected 3 days post implantation (EDD 10). Tumours grew to an
average size of ~140 mm3 by EDD 17 when left untreated (Fig. S1A).
The chicken vasculature in these tumours was efficiently perfused, as
demonstrated by the prompt distribution of India ink throughout the
tumour vasculature within 5 sec. after intravenous injection
(Fig. S1B). As expected, the tumour vessels were leaky, as the ink
was present in the extracellular space of the tumour already after
20 sec. (Fig. S1C).
Sub-optimal treatment strategies were defined, both for PDT
(Fig. 2A) and angiostatic compounds (Fig. 2C) in A2780. The PDT
conditions were selected such that tumour growth was inhibited
by ~60% (Fig. 2B). Dose selection for axitinib is shown in Fig-
ure 2D. For sorafenib, sunitinib and bevacizumab, the sub-optimal
doses in A2780 model were defined at 85, 71 and 497 lg/kg,
respectively. The same doses were applied in the HCT-116
model.
Combination of PDT and i.v. drug administration immediately after
and 24 hrs later was performed in the A2780 xenographs (Fig. 3A).
The representative images of tumours resected on treatment day 8
from different treatment groups are presented in Figure 3B. Photody-
namic therapy in combination with axitinib and sorafenib significantly
improved PDT outcome (**P = 0.0033 and **P = 0.0025, respec-
tively, Fig. 3C, N = 6–10). Surprisingly, sunitinib and bevacizumab
did not or only marginally improve the effect of PDT. Synergy, as
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Fig. 1 Clinically used angiostatic tyrosine kinase inhibitors prolong the vaso-occlusive effect of PDT. (A) Fluorescence angiograms of the CAM before
PDT. The circle represents the diaphragm, which limits CAM exposed with light. (B) 24 hrs and (C) 48 hrs after PDT showing the start of micro-
vascular regrowth and complete revascularization of the treated area, respectively. (C) Right panel shows the skeletonization and area numbers used
for the image processing. (D and E) Natural growth of CAM vasculature and inhibition of angiogenesis by axitinib and skeleton images of EDD 12.
White arrows indicate the avascular zones induced by axitinib. (F) Quantification of the number of branching points per mm2 after treatment with an
ineffective and an effective dose of each compound. Effective doses: axitinib (13 lg/kg; N = 7), sorafenib (85 lg/kg; N = 7), sunitinib (71 lg/kg;
N = 5) and bevacizumab (497 lg/kg; N = 5). (G) Fluorescence angiogram of the CAM treated with PDT+axitinib at its effective dose taken 48 hrs
post PDT. (H) Quantification of the results for all four tested compounds. Data are shown as means (SEM, **P < 0.01 as compared to the control
in each respective area of vascular regrowth (1–4), N = 3–6 per condition). The scale bars in (A, D and G) represent 200 lm.
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Fig. 2 Defining sub-optimal drug concentrations and PDT conditions for tumour treatment on the CAM. Treatment regimens for CAM tumours tested
for PDT alone (A) or drug alone (C). Tumour growth curves for PDT (B) and angiostatic drug (D) are shown. Arrows indicate treatment days. Data
are shown as means (SEM). N = 3–10 per condition; **P < 0.01.
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defined by the Chou-Talalay equation as combinations with a ‘combi-
nation index’ (CI) less than 1, was calculated for the combination of
PDT with axitinib (CI = 0.36) and PDT with sorafenib (CI = 0.59).
Neither sunitinib nor bevacizumab gave a statistically significant
difference in tumour size together with PDT as compared to PDT
alone. Similar experiments with axitinib and sorafenib were performed
on human HCT-116 colorectal carcinoma tumours. In this model,
comparable results were observed for PDT+axitinib (N = 6,
**P = 0.0008 as compared to the control) and PDT+sorafenib
(N = 9, *P = 0.02), as shown in Figure 6D (schedule 1) and G,
respectively, as a percentage of the control at the last day of the
experiment.
Combination therapy reduces vessel density and
modulates vascular morphology and
angiogenesis-related gene expression
Immunohistochemical staining for CD31 was performed 3 and 8 days
after treatment (Fig. 4) in both tumour models. It was found that the
combination of PDT and TKIs (both axitinib and sorafenib) sup-
pressed microvessel density as shown at the last (8th) experiment
day (Fig. 4A, **P = 0.0009, *P = 0.022, respectively and N = 6–
14). Angiogenesis inhibitors alone did not significantly suppress mi-
crovessel density (Fig. S2). Microvessel density in the bevacizumab
A
B
C
Fig. 3 PDT and anti-angiogenesis combination therapy. (A) Treatment regimens for CAM tumours treated with schedule 1. (B) Representative images
A2780 human ovarian tumours for control and various treated groups resected on treatment day 8. (C) Tumour growth curves of tumours treated
by each anti-angiogenic drug, PDT and the combination of both therapies (**P = 0.0033 for PDT+axitinib and **P = 0.0025 for PDT+sorafenib as
compared to PDT alone, (C) N = 6–10 per condition). S indicates synergy (CI<1).
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combination group was not different from the PDT monotherapy
group, while sunitinib combination group was increased as compared
to the control. Another interesting difference was observed in the
morphology of the tumour vessels. While control tumours had a large
numbers of small vessels with compressed lumens, the combination
of PDT with axitinib and sorafenib resulted in larger vessels with an
open lumen (**P < 0.001, *P = 0.051, respectively, N = 6–22,
Fig. 4A). Photodynamic therapy initially (treatment day 3, Fig. 4B)
suppressed microvessel density significantly, but after a longer period
(day 8) this effect had largely disappeared, presumably because of
the PDT-induced angiogenesis. Combination treatment of PDT + axiti-
nib of HCT-116 tumours revealed a statistically significant decrease in
vessel density (**P = 0.0006, N = 10) as compared to control
tumours resected at the last (8th) experiment day (Fig. 4C).
Based on the above-described results, we performed real-time
quantitative PCR studies for tumours exposed to axitinib and its com-
bination with PDT (Fig. 5A–C). We investigated the expression of
angiogenic growth factor receptors [26] in vasculature (chicken spe-
cific primers, 5A and B) and growth factors secreted by tumour cells
(human specific primers, Fig. 5C). It was observed that early after
treatment (day 3), i.v. administered axitinib, but not PDT, suppressed
VEGFR-2 in the vasculature. VEGFR-2 was still down-regulated 8 days
after treatment, at which time this effect was also seen for the expres-
sion of PDGFR-b. Assessment of growth factor expression in the
tumour cells (Fig. 5C) did not reveal a strong angiogenic response.
The change in the Ct values of the control and treatment group
tumours was examined between tumours excised on treatment days
3 and 8. A detectable, but not significant, change in gene levels was
noticed between days 3 and 8 in control tumours (data not shown).
The only significant increase in gene expression levels was noted for
VEGFA, whose expression was up-regulated by 10.7% in the host
cells on Day 3 versus Day 8 (*P = 0.044, N = 5–7) and by 11.7% in
the tumour cells between days 3 and 8 (*P = 0.052, N = 2–3).
Scheduling of PDT and angiostasis: lack of
vascular normalization
Next to the above used schedule (Fig. 6A, now called schedule 1), a
treatment schedule starting with angiostatic compounds axitinib
(Fig. 6B–D) or sorafenib (Fig. 6E–G) 24 hrs prior to PDT (schedule
2) was also tested in the two tumour models. Interestingly, none of
the angiostatic compounds applied prior to PDT (schedule 2) resulted
in significantly better anti-tumour photodynamic activity than for
schedule 1 at the conditions applied. While for sorafenib similar
results for schedule 1 and 2 were observed (Fig. 6E and G), for axiti-
nib treatment schedule 2 resulted in a worse outcome (Fig. 6B and
D), as compared to schedule 1 in both tumour models. In the HCT-
116 model, all tumours treated with combination therapy using either
schedule were inhibited significantly as compared to the control
tumours (control: N = 6–12; axitinib schedule 1: **P = 0.0008; axiti-
nib schedule 2: *P = 0.01; sorafenib schedule 1: *P = 0.022; and
sorafenib schedule 2: *P = 0.024).
The most unexpected result was that bevacizumab pre-treatment
even resulted in a loss of the anti-tumour activity resulting from the
PDT treatment (Fig. 6H). To further investigate the origin of differences
in tumour growth after treatment with the two schedules, intra-tumoral
oxygenation was measured at 24 hrs (when PDT was performed in
schedule 2) after the first bolus injection of axitinib (13 lg/kg), sorafe-
nib (85 lg/kg) and bevacizumab (497 lg/kg), see Figure 6C, F, and I,
respectively. The pO2 measurements performed 24 hrs after the first
injection with the inhibitors showed a small and not significant
increase in oxygenation (e.g. 6.7% for bevacizumab, as compared to
control tumours, P = 0.27, N = 10). Moreover, there was no differ-
ence between the latter groups and the PDT group.
Discussion
A major limitation in the use of PDT against cancer is the PDT-
induced angiogenic tissue response. As there are now many clinically
approved effective angiogenesis inhibitors, it is proposed that these
compounds can significantly prolong the beneficial angio-occlusive
effect of PDT [4]. The results of the present study show that angio-
static small molecule TKI can synergistically improve the anti-tumour
effect of PDT, in both an ovarian and a colorectal tumour model. A
major observation of this study is that this improvement of PDT out-
come was because of the inhibition of PDT-induced angiogenesis, and
not to the vascular normalization processes, as TKI-induced enhance-
ment of tumour oxygenation was not observed. Synergy between PDT
and anti-angiogenic TKIs for tumour growth suppression was best
observed for axitinib when applied at a sub-optimal dose and
combined with a sub-optimal PDT regimen. Sorafenib also showed a
synergistic activity, but these results were not observed for sunitinib
and bevacizumab. The results suggest that a combination of PDT and
axitinib might be a promising strategy for translation into the clinic.
Photodynamic therapy has been most successfully used in the
treatment of ophthalmological neovascularization-based disorders.
These were in the past mainly wet age-related macular degeneration
patients [27] and at present mainly patients with polypoidal choroidal
vasculopathy [28]. The treatment of solid tumours with PDT is cur-
rently receiving renewed interest because it is being realized that its
combination with anti-angiogenesis therapy has promising applica-
tions [4]. Several studies have been reported on such combinations
for the treatment cancer. These include pre-clinical studies assessing
the activity of cetuximab and/or bevacizumab with hypericin-PDT in a
human bladder carcinoma model [29], SU5416 and SU6668 with hy-
pericin-PDT in a human nasopharyngeal carcinoma model [30] and
PD166285 and PD173074 with hexylether pyropheophorbide-a-PDT
in a murine mammary carcinoma model [31]. In all these studies, the
anti-angiogenic drugs were applied after PDT, and the combination
treatment was shown to be more potent than the monotherapies. A
comparative study in which the PDT was combined in varying treat-
ment schedules, with clinically approved TKIs has not yet been per-
formed. In our study, the best results, i.e. a synergistic improvement
of PDT, were observed in combination with axitinib, making a clinical
translation of this treatment a promising option. This would most
likely be best developed for tumour types that have been shown to be
successfully treated with PDT, such as basal cell carcinoma (BCC) or
non-metastatic base of the tongue squamous cell carcinoma.
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Fig. 4 Histology of resected tumours showing microvessel density. (A) CD31-stained sections of the A2780 tumours excised at day 8 for control,
PDT and combination treatment groups. Graphs of microvessel density and the percentage of vessels with open lumens showing a statistically sig-
nificantly decrease in microvessel density and increase in the number of vessels with an open lumen for PDT+axitinib and PDT+sorafenib treated
tumours as compared to the control tumours. (B) CD31-stained sections of the A2780 tumours excised at day 3 for the most effective treatment
group (PDT+axitinib, 13 lg/kg) and quantification of microvessel density (right). (C) CD31-stained sections of HCT-116 tumours excised on day 8
and quantification of microvessel density (right) showing significant inhibition of vessel density in the combination PDT+axitinib treatment group.
**P < 0.01; N = 5–22 per condition.
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In BCC-diagnosed patients, the average recurrence was shown to
be 10% at 12 months after topical Metvix (methyl aminolevulinate)-
mediated PDT [32]. Unfortunately, the follow-up of these patients is
not continued longer than 1 year post PDT, whereas it was shown in
many studies that the recurrence peak post Metvix-PDT is at
36 months [33]. Moreover, patients treated with such PDT strategies
had a better cosmetic outcome and the treatment outcome was typi-
cally superior to that achieved with existing standard therapies [33].
Recurrent base of the tongue malignancies develop usually loco-
regionally at previously irradiated fields [34]. Also, interstitial PDT
(with metatetra(hydroxyphenyl)chlorin, mTHPC) of recurrent non-met-
astatic carcinoma of the tongue base showed promising results [35].
It is most interesting to see that when PDT was followed by angio-
genesis inhibition at the applied conditions, synergisms were
observed for axitinib and sorafenib, but not for sunitinib and bev-
acizumab. For the latter, there even seemed to be a lack of additive
effect (Fig. 3). It should be noted that part of the VEGF signalling in
this model may be derived from chicken VEGF, and bevacizumab
probably binds chicken VEGF with a lower affinity than human VEGF.
However, a number of studies have shown the efficacy of anti-VEGF
antibodies (bevacizumab or ranibizumab) against chicken VEGF, so
this argument may not be very significant [36]. The question remains
why neutralizing vascular endothelial growth factor (VEGF) does not
work so well, while inhibition of VEGFR signalling does. This could
mean that neutralization of VEGF by a large molecule—an antibody—
is much less efficient inside the microenvironment of a tumour in situ
than inhibiting the VEGFR by a small molecule. Another explanation
could be the broader activity spectrum of axitinib. This then raises the
question why axitinib works better than sunitinib. However, the most
likely explanation for this is that the affinity of axitinib for VEGFR-2 is
some 40 times higher [37].
A similar discussion is valid for the situation of angiogenesis inhi-
bition prior to PDT. Here, bevacizumab not only lacks improvement of
PDT but also seems to counteract the efficacy of PDT. Apparently, the
presence of VEGF is necessary for an effective PDT outcome. It can be
assumed that VEGF-induced active cell metabolism is necessary for
effective PDT. This also suggests that the major effect of PDT, at the
applied conditions, is through its effect on the vasculature. The fact
that the results from the axitinib treatment groups do not seem to sup-
port this option may be explained by the broad activity spectrum of
TKIs. Relatedly, this may also explain the overt difference between axi-
tinib and sunitinib, being the two drugs mainly inhibiting the VEGFRs.
Although VEGFRs and other growth factor receptors are considered
the primary targets of these compounds, it has been shown before that
more than one hundred kinases are affected by sunitinib [38], and it
would thus be quite difficult to pinpoint the exact mechanism of action
of these drugs [39]. Moreover, it cannot be ruled out that part of the
success of axitinib is through a direct activity on the tumour cells.
Another aim of this study was to study the consequences of the
treatment sequence. Previous studies on such combination therapies
for cancer were all performed by timing the angiostatic therapy
starting either at the same time as PDT, or after [31, 40, 41] PDT.
As suggested by Jain [42], angiogenesis inhibition can normalize the
tumour vasculature, as well as the blood flow, interstitial pressure,
vessel wall permeability and oxygenation. We and others have
shown that this effect of angiogenesis inhibitors can improve the
combination with e.g. chemo- and radiotherapy [43–45]. For exam-
ple, Dings et al. found a time-window of increased tumour oxygena-
tion over the first 4 days of treatment with either bevacizumab
(10 mg/kg i.v. in a single injection) or anginex (10 or 20 mg/kg/d
i.p.). Elevated oxygenation was also accompanied by reduced vessel
density and increased pericyte coverage. When radiotherapy was ini-
tiated within this window, tumour growth delay was significantly
enhanced in relation to alternative treatment schedules [43]. Huber
et al. [46] showed that SU11657 (a multi-target small molecule
inhibitor of VEGFRs and PDGFR) was more effective when adminis-
tered 1 day prior to radiotherapy as compared to 1 day after radio-
therapy. As PDT, like radiotherapy, is dependent on oxygenation of
the tissue, we put forward the hypothesis that anti-angiogenesis, at
least in some cases, could effectively be given prior to PDT. In the
A B C
Fig. 5 Real-time RT-PCR molecular profiling of the tumours treated with PDT, axitinib (13 lg/kg), or their combination. The expression of some of
the angiogenesis-related genes determined by quantitative real-time PCR performed at day 3 (A) and day 8 (B) post PDT using chicken (gg)-specific
primers for: VEGFA, VEGFR2, PDGFR-b. (C) Quantification of human genes in tumours excised on day 3 using human (hs)-specific primers for VEG-
FA, bFGF and PLGF. Mean relative expressions are shown with the SEM. N = 5–7 per condition.
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present study, we observed that the latter treatment schedule does
not improve the anti-tumour activity, or even, it can make the overall
outcome worse. This suggests that vascular normalization does not
take place to a significant extent at the applied conditions. Indeed, in
our experimental conditions, we did not observe significantly increased
oxygenation after treatment with axitinib (13 lg/kg), sorafenib (85 lg/
kg) or bevacizumab (497 lg/kg) over a period of 24 hrs. It should,
however, be noted that in these studies we used very low drug doses,
A
B C D
E F
H I
G
Fig. 6 Tumour growth rate depends on the treatment schedule. Treatments were performed at day 1 and 2 (black arrows) as indicated by the two
different schedules, shown in (A). Graphs show the effects of combination therapies with two different treatment schedules for axitinib in A2780 (B)
and in HCT-116 (D) tumours. Also for sorafenib (E) and bevacizumab (H) in A2780 and sorafenib in HTC-116 (G) tumours. In all cases, the most
effective treatment was combination therapy with treatment schedule 1. Measurements of intra-tumoral oxygenation in control, PDT, axitinib (C), so-
rafenib (F) and bevacizumab (I) treated A2780 tumours. Each group represents the mean  SEM (N = 3–8 per condition; **P < 0.01). Human
HCT-116 colon carcinoma growth rate inhibited by PDT+axitinib (**P = 0.0008) or PDT+sorafenib (**P = 0.022) applied at schedule 1, was similar
to that obtained in the A2780 model. Data are shown as means (SEM); N = 6–12 per condition.
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i.e. 0.497 mg/kg of bevacizumab, as compared to a dose of 10 mg/kg
reported to induce vascular normalization by Dings et al. [43].
To summarize the data from the current study, it can be con-
cluded that PDT and anti-angiogenic therapy can synergistically inhi-
bit tumour growth. Through the indirect neutralization of VEGF, and
the direct inhibition of growth factor receptors, the anti-tumour effect
of PDT can be improved.
Acknowledgements
The authors are grateful for financial support from Dr. J. Jacobi and the Swiss
National Science Foundation. Prof. Hubert van den Bergh is acknowledged for
expert assistance. Tse Wong is acknowledged for expert technical assistance. Host
institutes relevant to the work described include the Swiss Federal Institute of Tech-
nology, Centre Hospitalier Universitaire Vaudois, and the VU University Amsterdam.
Conflicts of interest
The authors confirm that there are no conflicts of interest.
Supporting information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Functional vasculature of a tumour growing on the
CAM. After injection of 30 ll of india ink into the CAM vessels
(A–C), the india ink is immediately distributed within the blood-
stream and perfused the tumour vessels within 5 sec. and tumour
interstitial space shortly after 20 sec.
Figure S2. Effect of anti-angiogenic inhibitors on microvessel den-
sity/mm2 in A2780 tumours. Quantification of microvessel density/
mm2 at day 8 of experiments for axitinib (13 lg/kg), sorafenib
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